AIP
TARA icon

Almanack Investment Partners’s Protara Therapeutics TARA Stock Holding History

Almanack Investment Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,782
Closed -$124K – 343
2026
Q1 		$124K Hold
23,782
– – 0.02% 170
2025
Q4 		$127K Buy
23,782
+10,288
+76% +$57.2K 0.02% 164
2025
Q3 		$58.7K Buy
+13,494
New +$43.7K 0.01% 194

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Almanack Investment Partners's TARA Position: Q2 2026 in Review

Almanack Investment Partners sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 23,782 shares — an estimated $124K sold.

Almanack Investment Partners first reported a position in TARA in Q3 2025 and held it in 3 quarters. The position peaked at $127K in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Almanack Investment Partners reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Almanack Investment Partners sold 23,782 Protara Therapeutics shares in Q2 2026, an estimated $124K.
  • Almanack Investment Partners first reported a position in Protara Therapeutics in Q3 2025 and held it in 3 quarters.
  • Almanack Investment Partners's Protara Therapeutics position peaked at $127K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.